Effect of Omega-3 Fatty Acid on the Fatty Acid Content of the Erythrocyte Membrane and Proteinuria in Patients with Diabetic Nephropathy
Table 5
Changes in erythrocyte membrane fatty acids content.
Olive oil ( = 8)
Omega-3 FA ( = 11)
Baseline
12 weeks
Baseline
12 weeks
Saturated
42.5 ± 6.1
37.7 ± 5.3
42.8 ± 8.3
39.8 ± 6.9
Myristic
0.62 ± 0.28
0.44 ± 0.10
0.79 ± 0.34
0.84 ± 0.48
Palmitic
25.2 ± 3.9
23.0 ± 2.9
27.5 ± 5.4
24.6 ± 2.9
Stearic
16.4 ± 3.7
14.0 ± 3.1
14.3 ± 3.1
14.1 ± 5.0
Lignoceric
0.27 ± 0.13
0.25 ± 0.14
0.27 ± 0.20
0.27 ± 0.25
Monounsaturated
17.2 ± 3.6
15.1 ± 2.3
17.8 ± 2.5
15.7 ± 1.4
Palmitoleic
1.2 ± 0.9
1.9 ± 1.7*
1.2 ± 0.7
1.8 ± 1.6
Transoleic
1.7 ± 1.1
2.0 ± 0.7
0.92 ± 0.61
1.9 ± 0.9
Oleic
15.5 ± 3.7
12.7 ± 1.3
16.2 ± 2.7
13.1 ± 2.2*
Polyunsaturated
37.4 ± 7.5
43.9 ± 6.6
37.5 ± 9.2
41.5 ± 7.4
Omega-6
26.7 ± 4.6
29.4 ± 5.1
27.6 ± 6.6
23.3 ± 4.7
Linoleic
13.9 ± 4.7
13.2 ± 2.7
14.7 ± 4.4
11.8 ± 3.8
AA
8.9 ± 3.2
11.7 ± 2.9*
9.8 ± 2.9
7.9 ± 2.9
Omega-3
10.7 ± 3.1
14.5 ± 2.8
9.8 ± 4.4
18.2 ± 8.4*
Alpha-linolenic
0.49 ± 0.24
0.45 ± 0.27
0.49 ± 0.21
0.49 ± 0.23
EPA
1.8 ± 0.6
2.9 ± 1.2
1.9 ± 1.4
4.2 ± 1.5*
DHA
6.1 ± 2.0
8.1 ± 1.2
6.0 ± 2.5
7.2 ± 3.2
Omega-3 index
7.9 ± 2.3
11.0 ± 2.1
7.9 ± 3.7
11.3 ± 4.6
AA/EPA
5.4 ± 3.0
4.7 ± 2.2
8.3 ± 7.4
1.9 ± 0.4*
Omega-6/Omega-3
2.7 ± 0.7
2.1 ± 0.5*
3.2 ± 1.3
1.5 ± 0.7*
Data are expressed as means ± SD. The nonparametric Wilcoxon exact rank sum test was used to compare baseline data with 12 weeks data. value <0.05 (mean values are significantly different from baseline). AA: arachidonic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid.
